G1 Therapeutics Inc

G1 Therapeutics — Investor Day (October 2019)

58 slides from G1 Therapeutics's investor day presentation, Oct 1, 2019

  1. Slide 1: ESMO 2019 Update

    ESMO 2019 Update 29 September 2019 Exhibit 99.3

  2. Slide 2: Agenda

    Agenda 6:45 – 6:50 p.m. Welcome & G1 Overview Mark Velleca, M.D., Ph.D., Chief Executive Officer 6:50 – 7:05 p.m. Breast Cancer State of the State c. 2019 Lisa Carey, M.D., FASCO, Chief of Hematology/Oncology and Physician-in-Chief, N.C. Cancer Hospital Associate Director of Clinical Sciences, Lineb

  3. Slide 3: Forward-looking statements

    Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expression

  4. Slide 4: Welcome & G1 Overview

    Welcome & G1 Overview Mark Velleca, M.D., Ph.D. Chief Executive Officer

  5. Slide 5: Small molecule therapeutics for big oncology indications

    Small molecule therapeutics for big oncology indications Breakthrough Therapy Designation; begin rolling NDA submission for SCLC in 4Q19, expect to complete in 2Q20 Preliminary OS benefit in mTNBC; initiating Phase 3 trial in 2H20 Initiating Phase 3 mCRC trial in 2H20 G1T48 Lerociclib Less neutropen

  6. Slide 6: Trilaciclib regulatory update

    Small cell lung cancer Triple-negative breast cancer Trilaciclib regulatory update Breakthrough Therapy Designation (BTD) Pre-NDA meeting with Hematology Division completed Will begin rolling NDA submission in 4Q19; expect to complete submission in 2Q20 Anticipate MAA submission in 2H20 Productive i

  7. Slide 7: Catalysts across all programs in 2019/2020

    Catalysts across all programs in 2019/2020 INDICATION/COMBO 4Q19 1H20 2H20 trilaciclib IV - CDK4/6i 1st-line SCLC (+ etop/carbo) Begin rolling NDA submission for SCLC Complete NDA submission for SCLC MAA filing for SCLC 1st-line SCLC (+ etop/carbo/Tecentriq) 2nd/3rd-line SCLC (+ topotecan) Initiate

  8. Slide 8: Breast Cancer State of the State c. 2019

    Breast Cancer State of the State c. 2019 Lisa A. Carey M.D., FASCO University of North Carolina Lineberger Comprehensive Cancer Center

  9. Slide 9: Disclosures

    Disclosures Research funding (to my institution): Innocrin, Nanostring, Novartis, Roche, Seattle Genetics Advisory or consultant role (no personal compensation): G1 Therapeutics, Innocrin, Lilly, Novartis, Seattle Genetics

  10. Slide 10: Epidemiology of Breast Cancer

    Epidemiology of Breast Cancer ~ 270,000 new cases per year in the U.S. (+2,500 men) in 2018 85% curable 3.5 million breast cancer survivors (currently in treatment and completed treatment) in the U.S.

  11. Slide 11: Clinical Receptor Phenotype

    Clinical Receptor Phenotype All Breast Cancer HR+ HER2+ Triple Neg

  12. Slide 12: Clinical Receptor Phenotype: Systemic Therapy

    Clinical Receptor Phenotype: Systemic Therapy All Breast Cancer HR+ HER2+ Triple Neg Primary Rx: Endocrine-based Anti-HER2-based Chemo-based

  13. Slide 13: Goals of Therapy

    Goals of Therapy Stages I-III / Nonmetastatic Cure No long-term toxicity Stage IV / Metastatic Control Tolerability (acute and chronic)

  14. Slide 14: Goals of Therapy

    Goals of Therapy Stages I-III / Nonmetastatic Cure No long-term toxicity Metastatic Control Tolerability (acute and chronic) Willing to tolerate more acute toxicity in order to complete Rx Balance toxicity and outcome Goals of therapy markedly differ

  15. Slide 15: Decision-making Regarding Need for Medical Therapy

    Decision-making Regarding Need for Medical Therapy Tumor size and appearance (grade) Local lymph node involvement Targetable receptors (ER, PR, HER2) Patient factors (comorbidities, age, etc.) Genomic assays (in ER+ HER2-) E.g. Oncotype Dx Recurrence Score, Prosigna, Mammaprint Medical therapy given

  16. Slide 16: Modern (Neo) Adjuvant Therapy

    Modern (Neo) Adjuvant Therapy Hormone receptor (ER, PR) + (regardless of HER2): Antiestrogen pills (5-10 years) Chemotherapy (several months) if high risk HER2+ (regardless of hormone receptors): Chemotherapy (several months) Anti-HER2 therapy (1-3 drugs for 1-2 years) “Triple negative” (all recepto

  17. Slide 17: Modern (Neo) Adjuvant Therapy

    Modern (Neo) Adjuvant Therapy Hormone receptor (ER, PR) + (regardless of HER2): Antiestrogen pills (5-10 years) Chemotherapy (several months) if high risk HER2+ (regardless of hormone receptors): Chemotherapy (several months) Anti-HER2 therapy (1-3 drugs for 1-2 years) Trastuzumab + pertuzumab + ner

  18. Slide 18: Breast Cancer Outcomes Have Improved

    Breast Cancer Outcomes Have Improved Better chemotherapy drugs and approaches Better endocrine therapy Development of anti-HER2 therapy 1986-1992 2004-2008 Cossetti R J et al. JCO 2015

  19. Slide 19: Nonmetastatic Breast Cancer Outcomes Have Improved

    Nonmetastatic Breast Cancer Outcomes Have Improved Better chemotherapy drugs and approaches Better endocrine therapy Development of anti-HER2 therapy 1986-1992 2004-2008 Cossetti R J et al. JCO 2015 Cost has also increased! Reason for focus on rational Rx

  20. Slide 20: Epidemiology of Metastatic Breast Cancer

    Epidemiology of Metastatic Breast Cancer Approximately 40,000 deaths per year in the U.S., but declining because of advances in therapy, especially in HER2+ disease Median survival ~3 years, but highly variable Prevalent population in U.S. ≈200,000 women

  21. Slide 21: Treatment Based on Tumor Phenotype

    Treatment Based on Tumor Phenotype Advanced Breast Cancer Requiring Therapy ER and/or PR Positive Endocrine therapy +/- additional Rx Refractory to Endocrine therapy ER and/or PR Negative Chemotherapy HER2 Positive Chemotherapy or ET + HER2 targeting HER2 Negative Chemotherapy Additional HER2-target

  22. Slide 22: ASCO Guidelines: General Principles

    ASCO Guidelines: General Principles ER+ HER2- Endocrine (usually) preferable to chemotherapy in 1st line Targeted agents added to ET (CDK4/6, mTOR, PI3K inhibitors) Any HER2- receiving chemotherapy Single agent chemotherapy preferable to combination Exception: symptomatic, immediately life-threateni

  23. Slide 23: Endocrine Rx Algorithm in ER+/HER2-

    Endocrine Rx Algorithm in ER+/HER2- (If premenopausal - OA/OS) PRIOR TREATMENT WITH TAMOXIFEN Early relapse Late relapse Aromatase inhibitor (AI) Fulvestrant (SERD) AI + CDK4/6i AI AI + fulvestrant AI + CDK4/6i Tamoxifen Fulvestrant ± palbociclib AI + everolimus AI Tamoxifen (late relapse) PRIOR TRE

  24. Slide 24: CDK4/6 Inhibitor Effect in HR+ HER2-

    CDK4/6 Inhibitor Effect in HR+ HER2- PALOMA2: Ph 3 letrozole + palbo 1stL PFS: 25m vs 14m OS immature MONALEESA7: Ph 3 ET + ribo 1stL pre/perimen Similar PFS impact CDK 4/6i across lines of Rx (~ HR 0.50) OS ↑ in pretreated pts with abemaciclib, ribociclib, (palbo trial immature). HR ~ 0.70-75. No a

  25. Slide 25: Alpelisib Added to Fulvestrant in PIK3CA mt HR+ HER2-

    Alpelisib Added to Fulvestrant in PreRx PIKC3CA mt HR+ HER2- Andre F, NEJM 2019 PIK3CAmt PIK3CAwt SOLAR1 PFS HR 0.65 in mutant group. No OS yet. Toxicity – hyperglycemia (40%), rash (10%)

  26. Slide 26: Fulvestrant vs AI: 1st-Line

    Fulvestrant Anastrozole P-value CR+ PR 46% 45% NS CBR 78% 74% NS PFS* 17m 14m 0.049 Robertson JFR et al, Lancet 2016 FALCON study: Phase III trial Fulvestrant as single agent =/> AI in 1st line endocrine Rx ET-naïve! OS 5.5m improvement in Phase II FIRST trial Considerations: Prior adjuvant AI (if a

  27. Slide 27: Chemotherapy in HER2-Negative Breast Cancer

    Chemotherapy in HER2-Negative Breast Cancer HR+ Disease Endocrine Rx Endocrine Refractory Disease CHEMOTHERAPY (Chemotherapy for ER+ and TN disease same. However + immunoRx only in TNBC) Triple Negative Disease

  28. Slide 28: Chemotherapy Options

    Chemotherapy Options Anthracyclines Doxorubicin Epirubicin Liposomal doxorubicin Taxanes Paclitaxel Docetaxel Nab-paclitaxel Vinca alkaloids Vinorelbine Other anti-tubule Eribulin Antimetabolites Methotrexate 5-FU Capecitabine Gemcitabine Alkylating agents Cyclophosphamide Platinum agents Epothilone

  29. Slide 29: Overall Survival in PD-L1+ Tumors with ImmunoRx added to Chemo

    Overall Survival in PD-L1+ Tumors with ImmunoRx added to Chemo 25.0 mo (22.6, NE) 15.5 mo (13.1, 19.4) 100 80 60 40 20 0 Overall survival 0 3 6 9 12 15 18 21 24 27 30 33 36 Months Stratified HR = 0.62 (95% CI: 0.45, 0.86) Atezo + nab-P (n = 185) Plac + nab-P (n = 184) OS events, n 64 88 2-year OS (9

  30. Slide 30: Summary

    Summary Nonmetastatic breast cancer is common and curable. Mainstays of therapy = chemotherapy, endocrine therapy, anti-HER2 depending on risk and type of cancer. Challenges – tailoring therapy, identifying if agents active in metastatic disease help reduce risk of recurrence if used (neo)adjuvantly

  31. Slide 31: ESMO Data Review: Trilaciclib and G1T48

    ESMO Data Review: Trilaciclib and G1T48 Raj Malik, M.D. Chief Medical Officer and Senior Vice President, R&D

  32. Slide 32: Trilaciclib mTNBC randomized Phase 2 trial: key findings

    Trilaciclib mTNBC randomized Phase 2 trial: key findings 102-patient three-arm trial; all groups received gemcitabine/carboplatin (GC), a single-day regimen Group 1 – GC only Group 2 – GC + trilaciclib on day of GC Group 3 – GC + trilaciclib on day prior to and day of GC Both trilaciclib arms showed

  33. Slide 33: ITT population overall survival and PFS

    ITT population Control (GC only) (Group 1) Trilaciclib + GC (Group 2) Trilaciclib + GC (Group 3) Trilaciclib + GC (Group 2+3) N = 34 N = 33 N = 35 N = 68 Median OS (months) 12.6 20.1 17.8 20.1 HR 0.33 0.34 0.36 p-value 0.028 0.0023 0.0015 Median PFS (months) 5.7 9.4 7.3 8.8 HR 0.60 0.59 0.59 p-value

  34. Slide 34: Significant overall survival benefit with trilaciclib

    Significant overall survival benefit with trilaciclib OS benefit greater than PFS suggests immune-mediated effect Based on data as of 17 May 2019 Group 1: GC only (Day 1/8) (n=34); Group 2: trilaciclib + GC (Day 1/8) (n=33); Group 3: trilaciclib + GC (Day 1/2/8/9) (n=35) ESMO 2019: Trilaciclib impro

  35. Slide 35: Overall survival subgroup analysis

    Subgroup No. of patients No. of events HR 95% CI Overall (ITT) 102 (100) 45 0.36 (0·19–0·67) Age <65 years 76 (74·5) 36 0.45 (0·23–0.91) ≥65 years 26 (25·5) 9 0.13 (0·03–0·63) Race White 78 (76·5) 33 0.26 (0·12–0·54) Non-white 24 (23·5) 12 0.92 (0·22–3·84) Liver involvement Yes 26 (25·5) 17 0.33 (0·

  36. Slide 36: G1T48 (Oral SERD) Update

    THERAPEUTICS G1T48 (Oral SERD) Update

  37. Slide 37: G1T48 Phase 1 trial: key findings

    G1T48 Phase 1 trial: key findings Well tolerated; favorable safety profile at all dose levels No dose-limiting toxicities observed; maximum tolerated dose not reached AEs mostly Grade 1 18F-FES PET scans – ER occupancy ≥ 80% in doses ≥ 400 mg Preliminary evidence of anti-tumor activity in heavily pr

  38. Slide 38: Favorable tolerability and safety profile; AEs mostly Grade 1

    Favorable tolerability and safety profile; AEs mostly Grade 1 Data cut: 12 August 2019 Drug-related adverse event Grade 1 Grade 2 Grade 3 Grade 4 Total (N=26) Fatigue 6 (23.1%) 1 (3.8%) 1 (3.8%) 0 8 (30.8%) Hot flush 5 (19.2%) 2 (7.7%) 0 0 7 (26.9%) Diarrhea 6 (23.1%) 1 (3.8%) 0 0 7 (26.9%) Headache

  39. Slide 39: PK/PD profile: robust target engagement

    PK/PD profile: robust target engagement ≥ 80% decrease in uptake at doses ≥ 400 mg Generally dose-dependent increases in exposure Food decreased variability and increases exposure Patients in expansion cohorts being dosed with food PK summary Dose-escalation study of G1T48, an oral selective estroge

  40. Slide 40: Heavily pre-treated patient population

    Heavily pre-treated patient population ~85% of patients had prior fulvestrant therapy ~65% of patients had received at least three lines of therapy N = 26 Patients % Prior fulvestrant 22 84.6% Prior CDK4/6 inhibitor 20 76.9% Prior chemotherapy 13 50.0% Last prior therapy duration ≤ 6mos 11 42.3% ≥ 3

  41. Slide 41: Efficacy demonstrated in heavily pre-treated population

    Efficacy demonstrated in heavily pre-treated population ORR=(CR+PR); CBR=(CR+PR+SD≥24 weeks) Response evaluable pts (N=19) ORR 1 (5.3%) CBR 3 (15.8%) Patient characteristics associated with PD by 8 weeks: Visceral disease ≥ 3 lines of prior therapy ≤ 6 months on most recent prior therapy Prior chemo

  42. Slide 42: ESMO 2019: key findings

    ESMO 2019: key findings Trilaciclib improved overall survival when added to GC regimen Well tolerated with improvement in anemia-related PRO measures Phase 3 trial beginning in 2H20 Favorable safety and tolerability profile Evidence of anti-tumor efficacy in heavily pre-treated population Phase 3 tr

  43. Slide 43: Q&A

    Q&A Dr. Carey, Dr. Malik & Dr. Velleca

  44. Slide 44: Pipeline Development Strategy and Regulatory Milestones

    Pipeline Development Strategy and Regulatory Milestones Raj Malik, M.D. Chief Medical Officer and Senior Vice President, R&D

  45. Slide 45: Trilaciclib: context-dependent efficacy

    Trilaciclib: context-dependent efficacy Weiss et al, Annals of Oncology 2019 He et al, Science Translational Medicine 2017 Bisi et al, Mol Cancer Ther., 2016 Tan et al, Lancet Oncology 2019 Zhang et al, Nature 2018 Jerby-Arnon et al, Cell 2018 Goel et al, Nature 2017 Deng et al, Cancer Discovery 201

  46. Slide 46: Trilaciclib benefits linked to setting

    Trilaciclib benefits linked to setting Primary Benefit: Myelopreservation Primary Benefit: Anti-Tumor Efficacy Chemotherapy schedule Multi-day regimens Single-day regimens Tumor type --- Tumor microenvironments more favorable to immune modulation Settings/indications: SCLC (etoposide + platinum, top

  47. Slide 47: Trilaciclib development plan

    Development plan targets broad myelopreservation label and anti-tumor efficacy label for specific tumors DISEASE OF INTEREST CHEMO REGIMENS 2020 2021 2022 2023 2024 2025 Myelopreservation 1L SCLC Etoposide + platinum, topotecan 1L mCRC 5-FU regimens Neoadj TNBC Doxo + cyclo + taxane Anti-tumor effic

  48. Slide 48: Lerociclib and G1T48 development plan

    DISEASE OF INTEREST COMBO DRUG 2020 2021 2022 2023 2024 2025 2026 2027 G1T48 1L ER+ mBC CDK4/6i 2L ER+ mBC Everolimus Neoadjuvant BC* N/A Adjuvant ER+ BC NA lerociclib 1L ER+ mBC Fulvestrant Adjuvant ER+ BC Aromatase inhibitor Lerociclib and G1T48: improving patient care in advanced/metastatic and a

  49. Slide 49: Commercial Opportunity and Strategy

    Commercial Opportunity and Strategy John Demaree Chief Commercial Officer

  50. Slide 50: Trilaciclib provides context-dependent efficacy

    Trilaciclib provides context-dependent efficacy: myelopreservation or improved survival TNBC: OS Improvement SCLC: Myelopreservation PLACEBO + CHEMOTHERAPY TRILACICLIB + CHEMOTHERAPY Patients (intent-to-treat population) 120 125 P-VALUE⁺ Mean duration (in days) of severe neutropenia in cycle 1 (SD)

  51. Slide 51: ~1 million chemo-treated patients in planned indications

    ~1 million chemo-treated patients in planned indications *Source: Secondary epi sources, 2027 estimates **EP refers to any regimen that includes etoposide + platinum; GC refers to gemcitabine/carboplatin; AC refers to any regimen that includes Adriamycin and cyclophosphamide; 5-FU refers to any regi

  52. Slide 52: Trilaciclib go-to-market strategy

    Trilaciclib go-to-market strategy Planning Capabilities Comprehensive launch plans across all functions All milestones on schedule Trilaciclib supply will be available at approval Hired experienced key functional talent at G1 Utilizing contractors for initial functional-level buildouts, including sa

  53. Slide 53: G1T48 and lerociclib: >350,000 1L and adjuvant BC patients

    G1T48 and lerociclib: >350,000 1L and adjuvant BC patients Duration** 14 months 33 months 60 months 25 months 60 months *Source: Secondary epi sources, 2027 estimates **Duration estimates based on similar trial results in the same or similar patient populations as planned trials G1T48 lerociclib Glo

  54. Slide 54: Q&A

    Q&A Dr. Malik, Mr. Demaree & Dr. Velleca

  55. Slide 55: Upcoming Catalysts and Closing Remarks

    Upcoming Catalysts and Closing Remarks Mark Velleca, M.D., Ph.D. Chief Executive Officer

  56. Slide 56: Catalysts across all programs in 2019/2020

    Catalysts across all programs in 2019/2020 INDICATION/COMBO 4Q19 1H20 2H20 trilaciclib IV - CDK4/6i 1st-line SCLC (+ etop/carbo) Begin rolling NDA submission for SCLC Complete NDA submission for SCLC MAA filing for SCLC 1st-line SCLC (+ etop/carbo/Tecentriq) 2nd/3rd-line SCLC (+ topotecan) Initiate

  57. Slide 57: Lisa A. Carey, M.D., FASCO biography

    Lisa A. Carey, M.D., FASCO is the Richardson and Marilyn Jacobs Preyer Distinguished Professor in Breast Cancer Research in the Department of Medicine at the University of North Carolina (UNC). She graduated from Wellesley College, then received her medical degree from the Johns Hopkins University S

  58. Slide 58: jmacdonald@g1therapeutics.com www.g1therapeutics.com Jeff Macdonald 919.907.1944

    jmacdonald@g1therapeutics.com www.g1therapeutics.com Jeff Macdonald 919.907.1944

G1 Therapeutics — Investor Day (October 2019) on 6ix